Allogene's ALLO-316 Shows Durable Responses in Metastatic Kidney Cancer
Event summary
- ALLO-316 achieved a 31% confirmed response rate in high CD70-expressing RCC patients.
- Median duration of response not reached, with responses lasting up to 18+ months.
- Phase 1b cohort showed manageable safety profile with no Grade 5 adverse events.
- Dagger® technology validated through robust CAR T expansion and tumor infiltration.
The big picture
Allogene's Phase 1 results for ALLO-316 represent a significant step forward in the challenging field of solid tumor CAR T therapy. The durable responses observed in metastatic kidney cancer patients validate the company's Dagger® technology platform, which addresses key barriers in allogeneic CAR T treatments. This success could accelerate development across Allogene's pipeline and position it as a leader in next-generation cell therapies.
What we're watching
- Clinical Validation
- Whether ALLO-316's durable responses can be replicated in larger trials.
- Pipeline Impact
- How the Dagger® technology's success will influence Allogene's broader pipeline.
- Regulatory Pathway
- The pace at which ALLO-316 advances through Phase 2 and potential FDA approval.
Related topics